UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): ~~May~~January 2211, ~~2017~~2018

PetLife Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Nevada

000-52445

33-1133537

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer

Identification No.)

38 West Main St., Hancock, MD		21750
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (844) 473-8543

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~Indicate 1by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.01405 of ~~Entry~~this ~~into~~chapter) aor ~~Material~~Rule ~~Definitive~~12b-2 ~~Agreement~~of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

OnEmerging ~~May~~growth ~~22,~~company 2017, PetLife Pharmaceuticals, Inc. (“PetLife”) and Dr. Ralph T. Salvagno, Dr. Vivekananda Ramana, and Dr. Baidvanath Mishra (collectively, Drs. Salvagno, Ramana and Mishra”), entered into an Assignment Agreement in regards to the following:[ ]

	●	On March 31, 2017, a patent was filed for the treatment of cancer in pets, combining chlorotoxin and plant-based therapeutics. The patent was filed in India titled A Composition for Targeting Cancer in Canines and Humans. The patent protection is for both process and composition thus protecting not only the physical elements of the formulation but also the process by which they are combined. This new patent pending advanced formulation will be the basis for PetLife’s product, Vitalzul™, for the proposed treatment of certain cancers in dogs and cats. The human application will be addressed by management at a later date.
	●	On May 9, 2017, the identical patent as filed in India, was filed with the United States Patent and Trademark Office.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

~~The~~Item ~~Assignment Agreement between PetLife and Drs~~2.03 ~~Salvagno,~~Creation ~~Ramana and Mishra provided an irrevocable assignment~~ of ~~all~~a ~~rights~~Direct ~~of the~~Financial ~~patent,~~Obligation ~~which~~or ~~will~~an beObligation ~~effected~~under ~~simultaneous~~an ~~with~~Off-Balance ~~the~~Sheet ~~issuance~~Arrangement of ~~each patent. Drs. Salvagno, Ramana and Mishra, in conjunction with the assignment, will be reimbursed for all expenses related to developing the intellectual property used as~~ a ~~basis for the patent, as well as other applicable expenses related to the patent~~Registrant.

~~Dr.~~On January 5, 2017, PetLife Pharmaceuticals, ~~Ralph~~Inc. ~~Salvagno~~(“PetLife”) isissued a convertible promissory note for $135,000 to EMA Financial, LLC (the ~~Chief~~“Note”). The ~~Executive~~Note ~~Officer~~bears interest at 12%, matures on January 5, 2019, and has a ~~Director~~conversion feature equaling the lower of ~~PetLife.~~the closing ~~Dr.~~sale ~~Ramana~~price isof the ~~Chief~~common ~~Medical~~stock ~~Officer~~on the principal market on the trading day immediately preceding the closing date or 60% of ~~PetLife~~either the lowest sale or closing bid price (whichever is lower) for the common stock on the principal market during the fifteen consecutive trading days including and immediately preceding the conversion date.

Item 9.01 Financial Statements and Exhibits.

The exhibits listed in the following Exhibit Index are filed as part of this report:

Exhibit No.		Description
10.6		Assignment Agreement between PetLife Pharmaceuticals, Inc. and Dr. Ralph T. Salvagno dated May 22, 2017
10.7		Assignment Agreement between PetLife Pharmaceuticals, Inc. and Dr. Vivekananda Ramana dated May 22, 2017
10.8		Assignment Agreement between PetLife Pharmaceuticals, Inc. and Dr. Baidvanath Mishra dated May 22, 2017
99.1		Press Release titled “PetLife Files for Patent for the Treatment of Cancer for Pets” as released on May 30, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the ~~Registrant~~registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PETLIFE PHARMACEUTICALS, INC.

PETLIFE PHARMACEUTICALS, INC.
(Registrant)

Dated: January 18, 2018	By:	/s/ Ralph T. Salvagno, MD
		Ralph T. Salvagno, MD
		Chief Executive Officer

(Registrant)

Dated: May 31, 2017	By:	/s/ Ralph T. Salvagno, MD
		Ralph T. Salvagno, MD
		Chief Executive Officer

Filing Compare · PetLife Pharmaceuticals, Inc.